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Introduction
Cardiovascular diseases (CVD) are the number one cause of death
in western societies [1, 2]. Atherosclerosis is the primary cause of
coronary artery disease (CAD) and stroke and is regarded as a
(chronic) inflammatory disease [3, 4]. Atherosclerosis is character-
ized by asymmetrical focal thickenings of the arterial intima that are
often referred to as atherosclerotic lesions or atheromas [5]. These
thickenings are caused by the accumulation of lipids and inflamma-
tory cells in the vessel wall [5]. Especially T cells and macrophages
play an important role in pathogenesis of atherosclerosis [6].
Besides lipids and inflammatory cells, the lesion – depending on
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Atherosclerosis is a multifactorial disease with a severe burden on western society. Recent insights into the pathogenesis of atherosclerosis
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basis of epigenetic regulation – and the contribution thereof in the regulation of inflammatory processes in general and during athero-
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the stage of the disease – further consists of vascular endothelial
cells (vECs) and vascular smooth muscle cells (vSMCs), and extra-
cellular matrix (ECM) [7]. Extreme thickening of the intima or even
plaque rupture with subsequent thrombus formation may seriously
hamper coronary blood flow, eventually leading to myocardial
infarction [8]. Thus, atherosclerosis is a potential life-threatening
condition and understanding the cause of atherosclerosis may con-
tribute to the treatment and possibly prevention of this disease.
Atherosclerotic plaque formation is a dynamic multi-cellular
process in which the activity of the different cell types involved is
essentially determined by the regulation of different genes [3–8].
Nowadays we are fully aware of the important involvement of epi-
genetic processes in the regulation of gene expression.
Understanding these processes is critical for our understanding of
inflammatory responses and disease. For instance, not only is
cytokine expression under epigenetic control, cytokines them-
selves induce (indirect) changes to the chromatin, providing an
essential link between inflammation and epigenetic programming
[9]. Here, we review the role of epigenetic regulation in vascular
remodelling and in the activity of immune cells involved in ather-
osclerotic plaque formation.
Epigenetics explained
Although all cells in our body contain the same genetic material,
each cell acts in a cell-type specific manner, as determined by its
gene expression profile. Epigenetic mechanisms control gene
expression without modifying the actual genetic code, while the
altered gene expression patterns can be passed on to the daughter
cells upon cell division or even transgenerationally [10–12].
In its natural state DNA is packaged into chromatin, a highly
organized and dynamic protein-DNA complex which consists of
DNA, histones and non-histone proteins [13]. Epigenetic mecha-
nisms alter the accessibility of chromatin by modifying DNA and
by modification or rearrangement of nucleosomes, which include
post-translational modifications of histones [14–16]. Accessible
chromatin allows gene-regulatory proteins (transcription factors)
to interact with their cognate binding sites within the regulatory
regions of genes, such as proximal promoters and enhancers/
silencers. In this way, global gene activation and local control of
gene-specific transcription is exerted by components of the epige-
netic machinery. Moreover, environmental factors have an impor-
tant role in the establishment of the epigenome [17–21]. Since
epigenetic alterations can accumulate in time, environmental fac-
tors can have profound effects on the cellular repertoire of
expressed genes [10].
Already in 1975 DNA methylation was proposed to play a role
in regulating gene transcription [22, 23]. Generally speaking, DNA
methylation is associated with low gene activity. Actively tran-
scribed genes are usually maintained in an unmethylated state in
their promoter regions [24–26]. DNA methylation involves methy-
lation at the C5 position of cytosine residues in a CpG dinucleotide
(i.e. cytosine followed by a guanine) context, exerted by DNA
methyltransferases (DNMTs). DNMTs are capable of both methy-
lation and demethylation – as has been postulated in two recent
reports – thus making the modification reversible [27, 28].
Notably, CpG dinucleotides are underrepresented in the genome of
eukaryotes, but can be found in clusters – so-called ‘CpG islands’
– which in turn are mainly found in promoter regions. The term
‘CpG island’ is defined as a region of at least 500 base pairs with
a CG content greater then 55% [29].
For many years it was thought that functionally relevant DNA
methylation occurs at the CpG islands within the promoter region.
However, in a recent study by Irizarry et al. it was shown that most
tissue-specific DNA methylation occurs in regions up to 2 kb dis-
tant of the promoter region [30], which were dubbed ‘CpG island
shores’ by the authors. Furthermore they showed that cancer-spe-
cific methylation also occurs at conserved tissue-specific CpG
island shores.
Besides methylation of DNA, post-translational modifications
of N-terminal tails of histone proteins are key components in the
epigenetic regulation of genes. Over 60 distinct modifications are
currently known – mostly in the histone tails – although some
have been observed in the globular domain [31, 32]. Modifications
of histone tails include (amongst others) acetylation and methyla-
tion of lysine residues. Whereas acetylation of histone tails is cor-
related with gene activation [33–35], the influence of histone
methylation depends on the exact residue methylated and the
number of added methyl groups [36–38]. Histone modifications
and DNA methylation provide a close interplay with respect to
gene regulation as both activities are functionally linked [39].
Whereas lysine methylation and acetylation are the most stud-
ied modifications, there are many more histone modifications
known. Arginine residues can also be methylated and acetylated,
just as lysine residues. As is the case with lysine methylation,
whether arginine methylation results in repression or activation of
transcription depends on which arginine residue is methylated
[40]. In addition, SUMOylation and ubiquitination of histones has
also been observed [32]. SUMOylation appears to be associated
with transcriptional repression [41], whereas ubiquitination has
been suggested to play a role in transcriptional activation and
elongation [42]. However, the exact function of these modifica-
tions remains to be elucidated.
Epigenetic alterations are reversible
Interestingly, epigenetic modifications are reversible, which is
illustrated by the counterbalancing actions of the various enzymes
that are responsible for maintaining the epigenome. Lysine acetyl-
transferases (KATs, formerly known as histone acetyltransferases)
are counteracted by lysine deacetylases (KDACs, formerly known
as histone deacetylases) and sirtuins in establishing histone
acetylation modifications at lysine residues in the N-terminal tails.
Lysine methyltransferases KMTs, (formerly known as histone
methyltransferases), finally, are counteracted by the recently dis-
covered lysine demethylases (KDMs, formerly known as histone
© 2010 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 14, No 6A, 2010
1227© 2010 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
demethylases) in establishing histone methylation modifications
(Fig. 1). In this way these enzymes promote a return to, respec-
tively, repressive or active chromatin structure [43–45].
Importantly, the reversible nature of these epigenetic modifica-
tions makes the chromatin-modifying enzymes interesting thera-
peutic targets [46–48] and a myriad of small molecule inhibitors
that can influence the enzymatic activity of these chromatin-mod-
ifying enzymes are currently being tested for their efficacy [49 and
references therein]. These inhibitors are mostly evaluated in the
field of cancer research, in cell lines, in animal models as well as
in clinical trials [49]. Notably suberoylanilide hydroxamic acid
(SAHA, or Vorinostat) and valproic acid (KDAC inhibitors [KDACi])
are already FDA approved for cancer treatment and epilepsy,
respectively [50–52]. With respect to atherosclerosis, administra-
tion of curcumin (a KAT inhibitor) resulted in significantly lowered
low-density lipoprotein levels and raised high-density lipoprotein
levels in healthy volunteers [53–55]. It has also been reported that
curcumin has an anti-proliferative effect on peripheral blood
mononuclear cells (PBMCs) and vSMCs [56].
Atherosclerosis
The first step in atherosclerosis is thought to be endothelial dys-
function [57], possibly triggered by oxidized low-density lipopro-
tein (OxLDL) [5]. Endothelial activation results in the expression of
cytokines and chemokines, enhancement in the permeability of the
endothelial cell (EC) layer and an increment in the expression of
adhesion molecules. Immune and inflammatory cells, such as
monocytes and T lymphocytes, are then attracted by chemokines
Fig. 1 Schematic representation of chromatin. DNA is wrapped around the octamer of core histones to form a structure called the nucleosome.
Transcriptionally active chromatin (euchromatin) is hallmarked by low frequency of DNA methylation. High levels of histone acetylation and histone methy-
lation correlated with activation (MeK4H3, MeK36H3, MeK79H3) are detected in euchromatin. KATs are responsible for acetylation of histone tails, KMTs
for methylation, whereas KDMs remove methylation marks of histones. DNMTs probably remove methylation marks from DNA, although this has not yet
been proven definitively (A). Transcriptionally silent chromatin (heterochromatin), is hallmarked by high frequencies of repressive methylation markers
(i.e. DNA methylation and MeK9H3, MeK27H3 and MeK20H4). Methylation of histone tails is catalysed by KMTs whereas DNA methylation is catalysed
by DNMT. Acetylation markers, associated with activation, are removed by KDACs (B). Post-translational modifications of histone tails include (but are
not limited to) acetylation (Ac) and methylation (Me), which can be associated with transcriptionally active (green) or silent (red) chromatin (C).
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(chemotaxis), followed by firm adhesion and transendothelial
migration. These cells subsequently infiltrate the subendothelium
of the vascular wall and form the main players in the formation of
the ‘fatty streak’ – the first identifiable lesion – (Fig. 2) [57].
Foam cells – cholesterol-engorged monocyte-derived
macrophages – are the dominant type of immune cells found
within the lesions. Macrophages take up the OxLDL present in the
subendothelium, but are unable to digest it sufficiently, resulting
in the formation of foam cells [5]. Although fatty streaks are not
clinically significant, they are thought to be the precursors to more
advanced lesions, although there is some dispute whether fatty
streaks are truly precursors of advanced lesions [7, 58]. If the
causative agents for this endothelial dysfunction are not effectively
removed, the inflammatory response can continue indefinitely.
The atherosclerosis-associated immune response is driven by
monocyte-derived macrophages and specific subsets of T cells [6,
59]. Monocytes and T lymphocytes migrate from the blood and
proliferate within the lesion, resulting in the accumulation of
inflammatory cells. If these cells become activated they release
cytokines, chemokines and growth factors [57], contributing to
the ongoing inflammatory process. Moreover, immune activation
eventually induces focal necrosis leading to the necrotic core
found in advanced lesions.
In later stages of the disease other cell types (e.g. vSMCs)
become involved. vSMCs start to proliferate as a response to the
various signalling molecules present in the lesion, thereby thick-
ening the arterial wall. Eventually the lesion will evolve into a
‘fibrolipid plaque’, consisting of a lipid-rich necrotic core covered
by a fibrous cap of vSMCs and a collagen-rich matrix [3, 60]. The
resulting thickening of the arterial wall caused by the plaque for-
mation will partially be compensated by gradual dilation (remod-
elling). If the plaque volume becomes too large, this process can-
not compensate enough, leading to decreased lumen size and
hampered blood flow [61].
As stated above, the development of the atherosclerotic lesion
is for the larger part determined by the release of various
cytokines and chemokines. Pro-inflammatory cytokines such as
tumour necrosis factor- (TNF-) and interferon- (IFN-)
released by activated T cells – recruited to the vascular cell wall –
play an essential role in disease development. This critical role for
pro-inflammatory cytokines in atherosclerosis development is
illustrated in atherosclerotic mouse models. It has been shown
that deletion of the genes coding for pro-inflammatory cytokines
(e.g. IL-12, IFN-, IFN-–receptor and TNF-) resulted in reduced
atherosclerosis development in these knockout mice [62–67].
Conversely, deletion of anti-inflammatory cytokine genes (e.g. IL-10
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Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Schematic representation of plaque development. OxLDL is thought to trigger endothelial dysfunction. OxLDL is often associated with proteogly-
cans in the subendothelium. Activated ECs start to express various adhesion molecules. Immune cells, mainly monocytes and T cells, are attracted by
chemokines and migrate across the endothelium, using adhesion molecules. Monocytes then differentiate into macrophages (M) and DCs. These
macrophages take op OxLDL and transform into ‘foam cells’. This process of foam cell formation is indicated with the large grey arrow. T cells recruited
to the plaque express several cytokines and chemokines. In response to the stimuli, vSMCs start to proliferate and migrate, and start to produce ECM.
Abbreviations: ECM: extra cellular matrix; EEL: external elastic lamina; IEL: internal elastic lamina; LDL: low-density lipoprotein; OxLDL: oxidized low-
density lipoprotein. Illustration inspired on [192].
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and TGF-) resulted in increased atherosclerosis [68, 69].
Different genetic variants of the TNF- gene also showed to be
important for the outcome of percutaneous coronary intervention
(PCI, one of the treatments used for opening of occluded vessels)
with respect to restenosis – one of the major limitations of the PCI
technique [66]. Genetic variants of the IL-10 gene have also
proven to be important for the development of restenosis [70].
The cross-talk between immune system and vascular wall
results in up-regulation of major histocompatibility complex
(MHC) class II (MHC-II) molecules and of the MHC class Ib mol-
ecule, HLA-E [3, 71]. Furthermore, it results in up-regulation of
chemokines such as CX3CL1 (fractalkine), CCL2 (MCP-1), CCL5
(RANTES) and their receptors [3, 72–75]. All of these factors influ-
ence the gene expression profiles of cells present within the
lesion. These observations not only feed the current theory that
atherosclerosis is an inflammatory disease – and not just a dis-
ease of lipid metabolism. For many of these inflammatory and
immune modulating factors epigenetic components have been
identified that are responsible for the transcriptional regulation of
the genes encoding these factors. Thus epigenetic processes
might prove to be important contributing factors to disease patho-
genesis that should be taken into consideration.
Epigenetics and association 
with atherosclerosis
Epigenetics provides an attractive explanation how diet, environ-
ment and lifestyle may contribute to disease. In principle, epige-
netics explains how such external factors can impose aberrant
gene expression patterns in an individual lifetime and even trans-
generationally. One of the earliest studies linking DNA methyla-
tion to atherosclerosis showed that the extracellular superoxide
dismutase (ec-SOD) gene was hypomethylated in atherosclerotic
lesions in rabbits [76]. The importance of DNA methylation as a
contributing factor to the pathogenesis of atherosclerosis is
underscored by a study linking global DNA hypermethylation with
predisposition to, and natural history of atherosclerosis [77]. In
this study the correlation was made by comparing methylation
sensitive restriction of peripheral blood leucocyte DNA. However,
this approach evaluates only the inflammatory component of the
disease process in PBMCs and not other components such as
vECs and vSMCs. In particular, DNA hypermethylation was found
to be significantly associated with both all-cause and cardiovas-
cular mortality, even following the adjustment for age, CVD and
diabetes mellitus. Hypermethylation was found in patients suffer-
ing from inflammation (high C-reactive protein levels) and also in
13 patients who died from CVD. This paper suggests that global
DNA hypermethylation is associated with inflammation and
increased mortality in chronic kidney disease. Importantly, hyper-
methylation was found to be the strongest independent risk fac-
tor for CVD mortality.
In the case of CAD an epigenetic component associated with
disease was also identified [78]. Sharma et al., found that angio-
graphically confirmed CAD patients showed a higher level of
genomic DNA methylation – determined in peripheral blood lym-
phocytes – when compared to healthy controls [78]. Furthermore,
a positive correlation was found between global DNA methylation
and homocysteine levels. Homocysteine is known to be an inde-
pendent risk factor for CAD [79, 80]. Sharma and coworkers also
tested the specific methylation status of the ApoE gene by bisul-
phite-sequencing. The ApoE promoter was previously shown to
have a degree of methylation that varies with homocysteine levels
[81]. However, no significant difference could be detected between
patients and controls [78]. Both these studies underline the poten-
tial effect DNA methylation can have with respect to disease devel-
opment and outcome. However, the precise genes targeted by
DNA methylation and thus the precise mechanisms that induce
DNMT activity remain to be elucidated.
Although DNA methylation is one of the most studied epige-
netic phenomena, more and more research is performed on the
specific contribution of histone modifications. Recently, a study
was published directly linking epigenetic histone modifications
and atherosclerosis. Hastings et al. showed that atherosclerosis-
prone shear-stress profiles globally decreased histone H4 acetyla-
tion and increased H4 acetylation at the c-fos promoter in smooth
muscle cells (SMCs) [82]. Perhaps more importantly, they
showed that atheroprone haemodynamics resulted in differentially
regulated phenotypes for ECs and SMCs. Shear stress (flow) was
applied to ECs that were layered on top of SMCs in forces that cor-
relate to atheroprone or atheroprotective conditions. Atheroprone
flow reduced the expression of endothelial nitric oxide synthetase
(eNOS), Tie-2 and kruppel-like factor in ECs, and smooth muscle
actin and myocardin in SMCs, whereas vascular cell adhesion
molecule 1 (VCAM-1), IL-8 and MCP-I were increased in both cell
types. This correlated to a decrease in total H4 acetylation and
serum response factor (SRF) binding to the SMC actin CArG-box in
the promoter region. Furthermore atheroprotective conditions
induced a polygonal shape in EC whereas atheroprone conditions
induced an elongated EC phenotype. In vSMCs atheroprotective
conditions induced an elongated shape whereas atheroprone condi-
tions showed a random SMC organization and cells aligned toward
a perpendicular orientation relative to the direction of flow [82].
Another linkage between atherosclerosis and histone modifi-
cations was found when the administration of the KDACi tricho-
statin A (TSA) in ldr/ mice led to exacerbated neointimal
lesions [83]. TSA increased CD36 mRNA, protein and cell surface
expression levels, which were related to increased acetylated his-
tone binding at the promoter region. CD36 recognizes OxLDL,
thus the obtained results might be due to increased OxLDL
uptake by macrophages. Also levels of TNF- and VCAM-1 were
increased in aortic plaques. It has also been noted that applica-
tion of TSA resulted in inhibition of SMC migration [84].
Unfortunately, the exact mechanisms are not yet fully understood,
but these studies clearly indicate a role for histone acetylation in
disease pathogenesis.
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Interestingly, some components relevant for the development
of atherosclerosis, such as OxLDL, are able to modulate the activity
of lysine deacetylases [85]. In cultured ECs it was shown that
OxLDL reduced expression of KDAC1 and KDAC2. Global KDAC
activities were partly restored by statins: pretreatment of ECs for
24 hrs with simvastatin or fluvastatin blocked the OxLDL-related
modifications in H3 and H4. Addition of mevalonate could revert
the effects observed after statin treatment. The researchers postu-
late that this, at least in part, may be due to inhibition of small
GTP-binding Rho proteins. Furthermore decreased expression of
KDAC2 in ECs was shown in atherosclerotic plaques of human
coronary arteries [85]. Taken together, these data show the impor-
tance of histone modifications in atherosclerosis.
A study performed by Barker et al. in 1989 sheds light on how
long-term cellular memory can have an effect on the development
of atherosclerosis. Nowadays it is generally accepted that long-term
cellular memory is mediated via epigenetic phenomena. Barker et al.
demonstrated that low birth weight is associated with a higher risk
of cardiovascular events in adult live [86]. This led to the hypothe-
sis that the environment the foetus is exposed to during pregnancy
might partially determine cardiovascular risk. This so-called ‘foetal
origins hypothesis’ states that adaptation to an unfavourable mater-
nal environment is beneficial to the developing embryo in utero
[86]. However, when the adult environment differs from the in utero
environment, this may lead to an increased risk for CVD. Studies in
pregnant rats show that a protein-restricted diet results in reduced
expression of Dnmt1, leading to hypomethylation of specific pro-
moters [87]. These observations provide a strong indication that the
in utero environment leads to epigenetic (re)programming, which
later in life might contribute to disease development.
Epigenetic regulation of cell activity
Cell differentiation (e.g. monocyte differentiation into macrophages)
and cell-specific gene expression in most cases is controlled by 
epigenetic mechanisms. Below we will discuss the most important
cellular factors that contribute to atherosclerotic plaque formation
and how their phenotype is regulated by epigenetic processes.
T cells
Several lines of investigation illustrate that T cells are important in
the formation of (early) lesions [88–91]. Within the plaque, sev-
eral subsets of T cells can be found. Mainly CD4 T cells are dom-
inantly found in plaques, but there are some CD8 T cells found
as well [5]. The T cells present in human plaques are predomi-
nantly of the Th1 phenotype [91]. Th1 cells produce IFN- – a
macrophage activating cytokine – and are generally considered
pro-atherogenic. Th2 cells are rarely detected in lesions [92]. They
are generally considered anti-atherogenic, but may also contribute
to aneurysm formation [93]. Regulatory T cells (Treg cells) control
the balance between Th1 and Th2. Tregs are considered to be
atheroprotective [94].
All T cells derive from the same precursor: the naïve T-cell. Not
surprisingly, differentiation of e.g. CD4 T cells into a Th1, Th2 
or Treg phenotype is regulated by epigenetic processes [95, 96]. The
differentiation of naïve T cells into Th1 or Th2 is determined by 
IL-12 and IL-4 cytokines, respectively. In response to these signals,
transcription is initiated of lineage specific cytokine genes including
IFN- and IL-4 [97]. The IFN- and IL-4 loci are maintained in a
poised state in naïve T cells, meaning they show both repressive
and activating epigenetic marks. In 1998 it was first proposed that
epigenetic, chromatin-based structural changes, underlie the
Th1/Th2 differentiation [98]. These epigenetic mechanisms – that
are necessary to stably maintain gene expression patterns and elim-
inate the need for feedback loops – will be discussed below.
In Th1 cells expression of IFN- is preceded by remodelling of
the IFN- locus [99]. Upon initial stimulation of naïve T cells, the
lineage determining factors GATA3 and T-bet mediate many of the
structural changes to the chromatin [95]. These factors will,
respectively, render the IFN- or IL-4 genes accessible to regula-
tory enzymes and other transcription factors [100–102]. On the
level of DNA methylation, there are numerous findings supporting
the epigenetic regulation of IFN- expression. Increased expres-
sion of IFN- was found in T cells from Dnmt knockout mice [103]
and in T cells treated with DNMT inhibitors (DNMTi) [104, 105]. In
addition, expression of IFN- by NK and NKT cells is also con-
trolled by epigenetic processes [99]. The ability of NK and NKT
cells to rapidly produce substantial amounts of IFN- implies that
the IFN- locus is accessible to transcription factors, meaning that
the chromatin at the IFN- locus is maintained in an ‘open’ state.
Indeed the IFN- locus in NK cells was found to be hyperacety-
lated and in a poised state [106, 107].
In the differentiation to Th2 cells, IL-4 expression is preceded
by remodelling of the IL-4 locus, similarly to the IFN- locus
remodelling in Th1 cells. In naïve T cells, the IL-4 locus is ‘poised’,
allowing rapid, early transcription. The IL-4 promoter region
exhibits a low basal level of H3 acetylation and DNA hypomethyla-
tion, but also shows 3MeK27H3 (i.e. triple methylation of lysine 27
on histone H3) modifications. When naïve T cells are stimulated
under Th1 conditions, transcription activating chromatin marks at
the IL-4 locus are replaced with repressive marks, whereas the
contrary happens under Th2 stimulating conditions (e.g. at the
IFN- locus). These processes have been excellently reviewed by
Ansel et al. [108 and references therein].
The Foxp3 transcription factor is considered the master switch
for Treg. The promoter of this transcription factor showed a differ-
ence in methylation levels between Tregs and non-Treg CD4 cells
[109]. Furthermore, this study also showed a difference in activat-
ing histone marks (AcH3, AcH4 and 3MeK4H3) in Foxp3 promoter
chromatin. Epigenetic regulation of T cell subtypes has also been
shown in vivo. Mice which were treated with the KDACi TSA
showed an increase in Foxp3 CD4 Treg cells – both proportion-
ally as well as in absolute numbers – in the lymphoid tissues [96].
Besides influencing T cell populations, the differentiation of mono-
cytes to dendritic cells (DCs) can also be modulated by KDACi [110].
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Monocytes
Monocytes are critical players in the formation of atherosclerotic
plaques. Monocytes migrate from the vessel lumen into the arte-
rial wall, where they differentiate into either DCs or macrophages
(Fig. 2). These macrophages later transform into foam cells, one
of the major components of the atherosclerotic plaque. It has been
shown by two independent researches that interfering with KDAC
function during differentiation resulted in the formation of func-
tion-impaired DCs. Notably, treatment with the KDACi’s butyrate
and MS-275 resulted in lowered expression of CD1. CD1 expres-
sion is a marker for mature DCs, but notably it is also important in
the presentation of lipid antigens and thus may play an important
role in the development of the atherosclerotic plaque [110, 111].
Endothelial cells
Epigenetic mechanisms are also directly involved in the transcrip-
tional regulation of immune genes in the vascular wall. For instance,
in cultured human ECs it was found that administration of the KDACi
TSA inhibited TNF- induced monocyte adhesion. This was the
result of down-regulation of the VCAM-1 gene; however, ICAM-1
and E-selectin – two other cytokines inducible genes – were not
affected [112]. This suggests that the KDACi modulated TNF--
mediated signalling specifically targets the VCAM-1 promoter,
instead of general inhibition of the NF-B pathway. This notion is
interesting, since NF-B is a target for chromatin modifying
enzymes as well (see ‘Non-histone targets’ below). Similar results
have been presented for the induction of tissue factor (TF) in human
ECs. The human TF promoter contains a NF-B related binding 
site: TF-B. KDACi administration inhibited agonist induced (TNF-,
IL-1 or LPS) TF activity in ECs by blocking activation of TF-B 
(TF activity was reduced 90% in HUVECs; 50% reduced in PBMCs, 
in vitro). TSA nearly abolishes TF-B binding, without affecting 
NF-B binding (as determined by electrophoretic mobility shift
assays (EMSAs), chromatin immunoprecipitation (ChIP) and
luciferase promoter reporter assays). These results were achieved
using a variety of structurally distinct KDACi’s [113].
Work performed in the group of Stefanie Dimmeler showed an
important role for KDACs in regulating several endothelial-specific
genes. Using KDACi’s, it was shown that eNOS mRNA and protein
levels decreased after KDACi administration [114]. Furthermore
the ‘master-switch’ for some typical endothelial expressed genes
(HoxA9, which regulates eNOS, VEGF receptor 2 and VE-cadherin
expression) was also down-regulated in its expression by KDACi
administration [115].
Smooth muscle cells
The data reported in literature regarding epigenetic regulation in
SMCs provides an explanation how epigenetics may control line-
age specificity. Nearly all SMC-restricted protein genes contain the
CArG box DNA sequence within their promoter and this sequence
is also required for SMC gene transcription in vivo. Genes impor-
tant for SMC phenotypic switching (e.g. genes important for
migration, proliferation and ECM production) also contain CArG
boxes within their promoters [116]. CArG boxes serve as a binding
site for the transcription factor SRF [117]. However, SRF expres-
sion is not limited to SMCs and serves many functions in different
cell types including cell migration and cell–cell adhesion [118].
Multiple pieces of evidence suggest that SRF binding to CArG
boxes in SMCs is regulated at the level of the chromatin structure.
First of all, the x-ray crystal structure of SRF showed that SRF
requires several contacts within the minor groove of DNA. The
minor groove would be obscured if DNA was wrapped around the
nucleosome structure. Also from thermodynamic considerations,
binding of SRF to the CArG box would be greatly inhibited if the
CArG box was bound to nucleosomes [119 and references therein].
Secondly, using EMSAs it was shown that SRF can bind to syn-
thetic DNA with the same affinity as to DNA obtained from lysates
of both SMC and non-SMC cell cultures. Conversely, by using
ChIP assays, it was shown that SRF binds to promoter regions in
SMCs much more effectively then to promoter regions in non-
SMCs. This suggests that in SMCs the chromatin is in such a state
that it is accessible to SRF [120–123]. This observation is sup-
ported by micrococcal nuclease digestion experiments, which
showed that the CArG-box of gene promoters in SMCs is more
accessible to digestion then in non-SMCs [124].
Finally, it was shown that histone H3 and H4 acetylation was
increased in SMCs when compared to numerous different cell-
types, including cultured endothelial stem cells. In addition, non-
SMCs were enriched for the repressive chromatin marks
3MeK27H3 and 2MeK20H4 at SMC-specific promoter regions
[119 and references therein].
Evidence from diabetic mouse models suggests an important
role for epigenetic regulation in the inflammatory phenotype of
vSMCs. The recently discovered KDM, lysine-specific demethy-
lase (LSD-1 or KDM1, a 2MeH3K27 demethylase), was shown to
play a role in the pro-inflammatory phenotype of vSMCs in dia-
betic mice [125]. In this mouse model levels of 2MeH3K4 (a his-
tone modification correlated with expression) were increased at
the MCP-1 and IL-6 promoters. Upon stimulation with TNF-
there was recruitment of RNA polymerase II to the promoter and
increased expression of MCP-1 and IL-6. Expression of LSD-1
was shown to be decreased in vSMCs. Knockdown of LSD-1 with
siRNA increased inflammatory gene expression whereas over
expression decreased inflammatory gene expression in vSMCs
of these mice.
It may very well be possible that similar mechanisms apply in
the case of atherosclerosis. As discussed in a previous section,
vSMCs isolated from rat thoracic aorta, which were treated with
the KDACi TSA, displayed an inhibition of vSMC proliferation [84].
It was subsequently shown that expression of p21WAF1 was
induced by this treatment. However, KDACi treatment had no
effect on SMCs isolated from p21WAF1 knockout mice.
Together, these findings illustrate that epigenetic mechanisms
play an important role in the processes that control differentiation
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and activation of haematopoietic cells, but also of vECs and
vSMCs [119, 126].
Chemokines, their receptors and other
genes involved in inflammation
Expression of immune response genes in vECs and vSMCs is a
major determinant in atherosclerosis onset and development
because it contributes to the vascular-immune cross talk. The vas-
cular wall modulates inflammation by the expression of numerous
cytokines and chemokines. For many of these genes epigenetic
components, influencing expression, have been identified. Below,
we will discuss some of the best-studied examples in detail.
eNOS
As stated in the previous sections, many inflammatory processes
are recognized by an epigenetic component. One of the best-stud-
ied cases of epigenetic regulation in the vascular wall involves the
transcription of eNOS, an enzyme which is regarded as endothe-
lial specific. Its catalytic product, nitric oxide, was first identified
as a vasodilator [127], although recent evidence also suggest a
role in inflammation. Nitric oxide has been attributed roles in leu-
cocyte adhesion and vSMC proliferation [128]. Furthermore, dys-
functional eNOS is believed to be implicated in atherosclerosis
development [129].
The human eNOS promoter does not contain a canonical TATA
box, nor does it contain a proximal CpG island. Expression of
eNOS is restricted to ECs in vivo. Various assays in both express-
ing and non-expressing cell types showed that a majority of the
non-expressing cell types displayed transgene promoter activity
[130–132]. In eNOS expressing ECs, eNOS promoter DNA was
only slightly methylated or unmethylated, whereas non-express-
ing cells showed a high amount of DNA methylation. Treatment of
non-expressing cell types with 5-azacytidine (a DNMTi) led to an
increase in eNOS mRNA levels [132]. Later experiments showed
the involvement of histone modifications in the expression of
eNOS as well. ChIP showed enrichment of AcH3, AcH4 and
(2/3)MeK4H3 in chromatin of the eNOS promoter in eNOS
expressing cells. Treatment of non-expressing cells with the
KDACi TSA – effectively increasing histone acetylation – also led
to an increase in eNOS mRNA [128 and references therein].
iNOS
Not only is eNOS regulated by epigenetic mechanisms, of interest
is the observation that also inducible nitric oxide synthase (iNOS)
is actively regulated by the epigenetic mechanisms [133]. This
gene is expressed in macrophages, but also in ECs and vSMCs,
under inflammatory conditions. It has been suggested that nitric
oxide – derived from macrophages expressing iNOS – can result in
apoptosis of vSMCs, promoting plaque instability [134]. A study
performed by Mellott et al. showed that cytokine induction of iNOS
resulted in a change of chromatin structure at the iNOS promoter
[9]. Later work showed that the NOS2A gene, encoding iNOS, had
high levels of DNA methylation and of the 2MeK9H3 and 3MeK9H3
repressive marks in non-expressing cells. Cell lines capable of
iNOS induction had lower levels of CpG-methylation and histone 
3 lysine 9 methylation at the NOS2A promoter. Treatment with a
DNMTi resulted in an increase of iNOS mRNA [133].
CCL11 (eotaxin)
In human atherosclerotic plaques, the chemokine CCL11 (also
know as eotaxin) was shown by immunohistochemistry to be
expressed [135]. In healthy tissue only negligible amounts of
CCL11 were found. Polymorphisms within the CCL11 gene are
also associated with the development of restenosis after PCI
[136]. CCL11, an eosinophil chemoattractant, has been suggested
to play a role in atherosclerosis development, although the precise
relation remains to be elucidated [135, 137, 138]. At the same
time CCL11 is expressed by SMCs, while macrophages in the
human atherosclerotic plaque express the CCL11 receptor, CCR3
[135]. CCL11 transcription is induced by inflammatory TNF- sig-
nalling and is mediated through NF-B. TNF- induces acetylation
of histone H4 in the CCL11 promoter. This results in an open chro-
matin structure, promoting subsequent binding of the NF-B sub-
unit p65 to the CCL11 promoter (as shown by ChIP) [139].
Notably, glucocorticoids repress CCL11 transcription through
selective inhibition of histone H4 acetylation [139]. Although only
histone H4 acetylation and no other epigenetic markers were
investigated, this research provides a very strong indication for
epigenetic regulation of the CCL11 gene [139].
CCR5
CCR5 is important for plaque formation as it attracts T cells and
mononuclear cells. Ccr5 knockout mice show less neointima forma-
tion and an increase in production of the anti-inflammatory IL-10
molecule by SMCs [140, 141]. One of the ligands for the CCR5
receptor, CCL5 or RANTES, has also been shown to be involved in
unstable angina pectoris (UAP) [142]. UAP is generally the result of
erosion or rupture of an atherosclerotic plaque. CCR5 is epigeneti-
cally regulated in T cells. In naïve T cells, lacking CCR5 expression,
DNA of the CCR5 receptor is hypermethylated and the acetylation
level of histone tails is strongly reduced in CCR5 promoter chro-
matin. When T cells are activated and express CCR5, DNA-methyla-
tion is significantly lowered combined with an increase in histone
acetylation modifications (our own unpublished observations).
The observations above indicate that epigenetic mechanisms
play a key role also in regulation of (immune) genes in cells that
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participate in atherosclerosis and vascular remodelling, and in the
cross-talk of immune cells and vascular wall components.
Epigenetics in (vascular) Inflammation
KDM6B
De Santa et al. recently showed that inflammation and Polycomb-
mediated gene silencing are linked [143]. Polycomb group (PcG)
proteins are important for the maintenance of a repressive chro-
matin state that is stable over many cell divisions. As such, PcG
proteins play a critical role in differentiation processes and main-
tenance of cellular identity. Gene silencing is mediated by the
Polycomb repressive complex 2 (PRC2) through the 3MeK27H3
chromatin mark, which is subsequently read by the PRC1 mainte-
nance complex [144 and references therein].
The JmjC-domain protein Jmjd3 (KDM6B, a H3K27 demethy-
lase) is expressed in macrophages upon stimulation with bacte-
rial products and pro-inflammatory cytokines [143]. Jmjd3
binds to PcG target genes, regulates 3MeK27H3 levels and
therewith their transcriptional activity [145]. For the first time, an
inducible enzyme was shown to erase epigenetic modifications.
Later work showed that 70% of lipopolysaccharide-inducible
genes in macrophages are Jmjd3 targets [146]. This provides an
essential link between inflammation and reprogramming of the
epigenome and might prove to be of vital importance in chronic
inflammation and autoimmune diseases including atherosclero-
sis in the near future.
Oestrogen receptor
Oestrogen receptors (ERs) are present in the coronary arterial wall
on both SMCs and ECs [147–149]. ERs may play an important role
in protection against atherosclerosis [148]. Deficiencies in ER-
lead to accelerated atherosclerosis in men, furthermore ER- medi-
ates the loss of expression of some cytokine induced cell-adhesion
molecules [150 and references therein]. ER  was shown to have a
varying degree of methylation throughout the cardiovascular sys-
tem [151]. In the same study it was shown that an age related
increase of methylation occurred in the right atrium. Furthermore,
higher degrees of methylation were found in coronary atheromas
when compared to macroscopically normal tissues.
Similarly, the ER- also displays a correlation in methylation of
its promoter and atherosclerosis [152]. Contrary to ER- expres-
sion, expression of ER- correlates with atherosclerosis inde-
pendent of age [153]. By comparing plaque versus non-plaque tis-
sue from the same vessels, it was recently shown that the ER-
promoter has higher methylation levels in atherosclerotic lesions
[152]. In this study, increased expression of ER- was also
observed – in vitro – in ECs and SMCs after administration of a
DNMTi (5-aza-2	-deoxycytidine) and a KDACi (TSA). These exper-
iments provide supporting evidence for epigenetic regulation of
the ER- receptor.
COX2
Another example for the linkage between epigenetics and CVD-
related inflammation is transcription of the cyclooxygenase-2
(Cox-2) gene. TNF- – as well as several other cytokines – can
induce expression of Cox-2, a protein associated with athero-
sclerosis development [154]. Cytokines (such as TNF- and
IFN-) can also induce (indirect) changes to the chromatin,
allowing effector genes to be expressed upon stimulation [9].
For Cox-2 it was demonstrated that mRNA expression and pro-
tein synthesis can be repressed in vitro, in cell lines by the
KDACi’s sodium butyrate and TSA revealing a significant role for
epigenetic components in Cox-2 expression [155]. These exper-
iments were performed in a colon cancer cell line, and thus
need to be confirmed in cells relevant for vascular biology and
atherosclerosis (e.g. vECs, vSMCs or monocytes) to extrapolate
these results to atherosclerosis.
Transcriptional regulation of MHC 
molecules – the role of CIITA
Constitutive expression of MHC-II surface molecules is restricted
to professional antigen presenting cells (APC) of the immune sys-
tem. On all other cell types their expressions can be induced in an
environment rich in inflammatory cytokines – such as the athero-
sclerotic plaque – or upon activation such as in human T cells
[156]. Therefore under inflammatory conditions MHC-II molecule
expression can be induced on vECs and vSMCs, which normally
are not expressing MHC-II [157, 158].
The ‘master regulator’ of MHC-II expression is the co-activator
CIITA (class II transactivator) [159]. Within the context of athero-
sclerosis, CIITA is of importance, since it has been shown to be
involved in transcriptional regulation of collagen type 1 [160, 161].
Collagen 1 is one of the main components of ECM and is essential
in cap formation and plaque stabilization [57].
Transcriptional regulation of MHC2TA, the gene encoding
CIITA, is mediated through the activity of four independent pro-
moter units (CIITA-PI through CIITA-PIV, Fig. 3) [162]. These pro-
moter units are employed in a cell type- and activation-specific
manner. In aortic SMCs CIITA-PIII and -PIV are expressed after
IFN- stimulation and CIITA is needed for IFN-–mediated repres-
sion of collagen type 1 genes (COL1A1 and COL1A2) [160, 161].
Furthermore, collagen transcription is also repressed by the RFX
family proteins. RFX1 only weakly interacts with the unmethylated
collagen promoter, but binds with higher affinity when the pro-
moter is in a methylated state [161].
In MHC-II transcription, CIITA exerts its transactivating func-
tion through protein–protein interactions with a multi-protein
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complex, which comprises RFX, CREB/ATF and NFY (Fig. 3B)
[163–165]. Together with CIITA, this complex acts as an
enhanceosome driving transactivation of these genes [163–165].
In the MHC-enhanceosome, CIITA acts as a platform for recruit-
ment of chromatin-modifying activities which include KATs,
KDACs and an arginine methyltransferase [166–168]. Interactions
of these chromatin-modifying enzymes and CIITA result in higher-
order structural changes within the chromatin, effectively activat-
ing or silencing MHC-II gene transcription [167, 169]. A number
of studies now have shown that epigenetic processes not only
control MHC-II transcription, but also contribute to the activat-
ing/silencing of MHC2TA transcription. This is illustrated by the
observation that in DC maturation deacetylation occurs at the
MHC2TA locus coinciding with transcriptional inactivation [170].
During DC differentiation histone acetylation of the type I pro-
moter is increased. This increase was blocked by IL-10, inhibiting
MHC2TA transcription [171].
Non-histone targets
Acetyltransferases/deacetylases and methyltransferases/demethylases
discussed in the previous sections also target non-histone pro-
teins which could lead to alterations in function of the targeted
proteins or the generation of novel epitopes which now can evoke
an adaptive (auto-) immune response [172]. Especially since NF-
B – playing crucial roles in inflammation – is showing up as one
of the non-histone substrates. Both NF-B and p53 are acetylated
by KAT3A (CBP) and KAT3B (p300) [173–176], whereas p53 can
also be acetylated by KAT2B (PCAF) [177, 178].
As is the case with most genes, transcription of pro-inflamma-
tory cytokine genes such as IFN- and TNF- is positively regu-
lated by transcription factors. However, these cytokines can also
induce changes to the epigenome. Thus not only are cytokines
under epigenetic control, cytokines themselves induce (indirect)
changes to the chromatin, allowing effector genes to be expressed
upon stimulation. Activation of the IFN- pathway results in 
activation of e.g. NF-B. NF-B is found in the cytoplasm of
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Fig. 3 Organization of the MHC2TA
multipromoter region. Each pro-
moter (indicated with black arrows)
transcribes a unique first exon
(coloured boxes). Transcription
start sites are indicated with
coloured, angles arrows. Promoter
PI is mainly used for constitutive
CIITA expression in DCs, whereas
PIII is mainly used in B Cells, acti-
vated T cells and macrophages.
Promoter PIV is mainly used for
IFN- induced CIITA expression in
non-bone-marrow-derived cells.
The function of PII is still poorly
understood (A). Factor assembly on
the MHC-II promoter. Shown is the
regulatory SXY module, to which
the MHC enhanceosome binds (B).
Gene Type of regulation References
ec-sod DNA methylation [76]
c-fos Histone code [82]
CD36 Histone code [83]
IFN- DNA methylation and histone code [99–101]
IL-4 DNA methylation and histone code [108]
Foxp3 DNA methylation and histone code [109]
eNOS DNA methylation and histone code [128, 132]
iNOS DNA methylation and histone code [9, 133]
CCL11 Histone code [139]
CCR5 DNA methylation and histone code Own observations
ER- DNA methylation [151]
ER- DNA methylation and histone code [152]
CIITA DNA methylation and histone code [166–171]
Table 1 Overview of genes regulated by epigenetic processes involved
in atherosclerosis development. Genes for which evidence of epigenetic
regulation is solely based on administration of inhibitors of histone
modifying enzymes are not shown.
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unstimulated cells, together with its inhibitor, IB, that prevents
NF-B from entering the nucleus [179]. Upon stimulation with
inducers – e.g. reactive oxygen species (ROS) and lipid peroxidase
products – IB is rapidly degraded via the ubiquitin–proteasome
pathway [180, 181]. Hereupon, NF-B is transported to the
nucleus, where it can activate the transcription of various targets
with B-elements in their promoter [182, 183]. This process is
known to be activated by KATs and repressed by KDACs [172 and
references therein]. The p65 subunit of NF-B is acetylated by
KAT3A/B (P300/CBP) at lysines 218, 221 and 310 [184]. The
acetylated form of p65 shows weak affinity for IB. KDAC3 in turn
deacetylates p65, promoting association with IB and thereby
nuclear export of NF-B [175]. In addition to KDAC3, KDAC1 has
been shown in vitro and in vivo to deacetylate p53 [185].
Besides to acetylation, methylation of non-histone proteins has
also been observed. For example, methylation occurs at lysine 831
of the vascular endothelial growth factor receptor 1, which is di-
methylated by Smyd3 (a H3K4 methylase) [186]. The biological
function of methylation at lysine 831 is yet to be discovered.
These examples perfectly illustrate how epigenetic and inflam-
matory processes are interwoven.
MicroRNAs
In recent years it became apparent that microRNAs (miRNAs) are
critically involved in the regulation of gene expression. Synthesized
as a larger precursor in the nucleus, miRNAs are processed in the
cytoplasm into mature miRNAs, where they target specific mRNAs
for degradation or translational inhibition [187]. A large number of
miRNAs have already been identified at the moment and, not sur-
prisingly, miRNAs have also been found to be involved in inflam-
mation and atherosclerosis [188]. Unfortunately for most miRNAs
the target they act upon is yet to be identified.
For some miRNAs, which might play a role in atherosclerosis
development or inflammation the miRNA target gene has been
identified. For instance the EC specific miR-126 inhibits the (TNF-
 mediated) expression of VCAM-1 [189, 190]. This miRNA might
thus be involved in transmigration of mononuclear cells into the
subendothelium. Several other miRNAs have also been identified
to be involved in inflammation [191 and references therein].
Conclusions
Epigenetic control is one of the most fundamental regulatory sys-
tems within the cell. Not surprisingly it fulfils essential roles in the
regulation of inflammatory and immune responses (summarized
in Table 1). The link between inflammation and reprogramming of
the epigenome, shown by the induction of jmjd3 after LPS treat-
ment, is an important discovery. Furthermore, the involvement of
KDM1 in the inflammatory phenotype of vSMCs is of importance,
as it does provide evidence for a link between inflammation and
epigenetics, relevant for atherosclerosis. Correlations between
global DNA methylation and atherosclerosis have provided valu-
able clues that epigenetics plays a role in atherosclerosis develop-
ment; however, it remains to be further elucidated which genes are
directly affected by DNA methylation.
Similarly, precise determination of histone modifications at spe-
cific genes might prove its value in understanding gene expression
profiles in vascular disease. Especially since small molecules can
inhibit the function of histone modifying enzymes, altering the
expression of genes. Therefore intervention in epigenetic gene reg-
ulation might prove to be the therapeutic intervention of the future,
especially in complex multi-factorial diseases such as atheroscle-
rosis, multiple sclerosis and rheumatoid arthritis.
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